Publications by authors named "Ward F M Posthuma"
Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. To this end, baseline serum samples of 51 CLL patients treated with chemo-immunotherapy were analyzed for 360 proteomic markers, using Olink technology.
View Article and Find Full Text PDFFeasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Arnon P Kater Marinus H J van Oers Yvette van Norden Lina van der Straten Julia Driessen Ward F M Posthuma
Haematologica
January 2019
Article Synopsis
- Lenalidomide is effective in treating chronic lymphocytic leukemia (CLL) but has a challenging toxicity profile, which can impact combination treatments.
- A phase 1-2 study evaluated a treatment regimen combining chlorambucil, rituximab, and variable doses of lenalidomide, showing that 89% of patients completed the initial treatment cycle, with an 83% overall response rate and a median progression-free survival of 49 months.
- While some significant toxicities were observed, including high rates of neutropenia, the study concluded that lenalidomide combined with chemotherapy and sequential monotherapy achieves promising remission rates and manageable toxicity through individualized dosing.